RxDoctor Payments Data

Tatiana Alexeev

Glenview, ILNPI 1902268410

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $106,963 of the $120,354 with a category attached, or 88.9%. AbbVie accounts for 99.9% of it on its own, with 1 other manufacturer making up the rest.

$120,354in general payments, 2019–2025

Across 268 payments — averaging $449.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$120K
  • Galderma Laboratories, L.p.$156

What the payments were for

  • Consulting fees$1680%
  • Speaking & faculty fees$106,96389%
  • Travel & lodging$6,2165%
  • Food & beverage$6,7826%
  • Education$2260%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)259$120,197
Galderma Laboratories, L.p.9$156

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →